Logo for JMJ in standard indigo Logo for JMJ in standard indigo
  • SolutionsExpand or Contract
    • Transform your organization’s safety, sustainability and performance.
      • Safety
        • Safety Leadership
        • Incident and Injury-Free™ (IIF™)
        • Incident and Injury-Free™ (IIF™) Fleet
      • Sustainability
        • Sustainability Leadership
      • Performance
        • Performance Leadership
        • High-Performance Projects™
    • Whatever industry you’re in, wherever you operate in the world, we’re here to help.
      • Construction
      • Energy
      • Infrastructure
      • Manufacturing
      • Technology
      • Case Studies
  • Transformation Cloud
  • Insights
  • About
  • Contact Us
menuMobile Navigation Menu
EHS for Biopharma Summit

Highlights from the EHS for Biopharma Summit, 2024

Challenges, initiatives and talking points.

EHS for Biopharma Safety Culture Safety Leadership
Share on
  • facebook
  • twitterbird
  • linkedin
Events

|By JMJ

| March 11, 2024

Jennifer McKeon and Lindsay Speed represented JMJ at the EHS for Biopharma summit in Boston on February 28 and 29. The summit was well attended, drawing EHS VPs, directors, managers, and specialists from leading companies, all striving for the highest standards of Environmental Health and Safety amid rapid industry change.

Jennifer and Lindsay share key challenges, initiatives and discussions from the two-day event.

Key safety challenges identified:

  • Risks in BioPharma environments are often underestimated
  • Companies often feel they have to choose between safety and quality
  • Effective R&D leadership doesn’t always translate to effective safety leadership
  • Environmental Health and Safety (EHS) practices should be integrated with business operations for comprehensive risk management
  • The multi-generational workforce brings cultural and mindset differences, impacting risk perception and tolerance

Initiatives companies are adopting to overcome these challenges:

  • Strategies such as an annual pulse survey are helping organizations measure leadership engagement
  • Use of QR codes is encouraging proactive risk management
  • Green Lab initiatives are proving valuable for sustainability and safety enhancement
  • Novo Nordisk’s initiative to launch EHS training for sales teams highlights a holistic safety approach
  • Adoption of NIOSH‘s Total Worker Health initiative prioritizes employee well-being

Other notable discussions:

  • Larger companies recognize opportunities for enhancing safety within their fleet operations
  • Importance of scrutinizing supply chains to ensure safety standards are maintained throughout
  • Inclusion of occupational physicians in safety committees
  • Awareness of “watermelon metrics”- ones that appear to be green and on target but beneath the surface are all red – underscores the importance of transparent safety measurement

Jennifer and Lindsay would like to thank the organizers Hanson Wade, speakers and attendees for sharing their insights and strategies for navigating the complex safety challenges of the Biopharma industry.

Did you attend the EHS for Biopharma Summit? We’d love to hear your takeaways from the event. Contact us.

Related Industries

Related Solutions

Safety Safety Transformation
Insights from JMJ

Keep up with the latest news and views

JMJ
  • facebook
  • twitterbird
  • youtube
  • linkedin
  • SolutionsExpand or Contract
    • Safety
      • Safety Leadership
      • Incident and Injury-Free™ (IIF™)
    • Sustainability
      • Sustainability Leadership
    • Performance
      • Performance Leadership
      • High-Performance Projects™
  • Industries
    • Construction
    • Energy
    • Infrastructure
    • Manufacturing
    • Technology
  • Digital
  • Company
    • About Us
    • Leadership
    • Careers
    • Insights
  • Locations
    • Austin
    • Atyrau
    • Doha
    • London
    • Mumbai
    • Sydney
    • Seoul
    • Shanghai
    • Singapore

© 2025 JMJ
Republication or redistribution of JMJ Associates content or logo, including by framing or similar means, is prohibited without the prior written consent of JMJ Associates.

Privacy | Cookie Policy | Terms of Use | Trademarks